Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
June 17, 2022
- New NIBIOHN Chief Eager to Bridge Void to Develop Innovative Drug Discovery Platform
June 17, 2022
- First Two Vaccine Projects Adopted for SCARDA Funding
June 17, 2022
- Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
- MHLW Proposes KPIs for Creation of Drug Discovery Ecosystem, 3 Other Areas
June 15, 2022
- Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
- MSD and Pfizer COVID Pills Add Anaphylaxis in ADR List: Label Update
June 15, 2022
- MHLW Publishes Guidelines for Evaluating SaMDs Used for Behavioral Modification
June 15, 2022
- Lawmakers’ Group Pushes for Legal Steps to Eliminate Drug Lag for Children
June 14, 2022
- LDP’s COVID HQ Compiles Mid-to-Long Term Proposal for Future Pandemics
June 14, 2022
- MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
June 14, 2022
- Updated Labels for mRNA Vaccines Flag Risk of Guillain-Barre Syndrome
June 13, 2022
- Japan Mulls Securing AstraZeneca COVID Cocktail If Approved: Minister
June 13, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Pharma Wants Govt Purchase for Novel Antimicrobial, Instead of Favorable Pricing
June 10, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…